FCGRT

Summary

FCGRT (Fc gamma receptor and transporter, HGNC:3621) is a protein-coding gene on chromosome 19q13.33, encoding IgG receptor FcRn large subunit p51 (P55899). Cell surface receptor that transfers passive humoral immunity from the mother to the newborn.

This gene encodes a receptor that binds the Fc region of monomeric immunoglobulin G. The encoded protein transfers immunoglobulin G antibodies from mother to fetus across the placenta. This protein also binds immunoglobulin G to protect the antibody from degradation. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 2217 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 65 total
• Druggable target: yes
• MANE Select transcript: NM_001136019

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3621
Approved symbol	FCGRT
Name	Fc gamma receptor and transporter
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	FcgammaRn, FcRn
Ensembl gene	ENSG00000104870
Ensembl biotype	protein_coding
OMIM	601437
Entrez	2217

Gene structure

Transcript identifiers

Ensembl transcripts: 62 — 53 protein_coding, 5 retained_intron, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000221466, ENST00000426395, ENST00000452439, ENST00000593381, ENST00000593431, ENST00000594823, ENST00000595677, ENST00000595881, ENST00000596147, ENST00000596975, ENST00000598076, ENST00000598319, ENST00000598491, ENST00000598927, ENST00000598936, ENST00000599701, ENST00000599988, ENST00000600273, ENST00000899035, ENST00000899036, ENST00000899037, ENST00000899038, ENST00000899039, ENST00000899040, ENST00000899041, ENST00000899042, ENST00000899043, ENST00000899044, ENST00000899045, ENST00000899046, ENST00000899047, ENST00000899048, ENST00000899049, ENST00000899050, ENST00000899051, ENST00000899052, ENST00000899053, ENST00000899054, ENST00000899055, ENST00000899056, ENST00000899057, ENST00000899058, ENST00000899059, ENST00000899060, ENST00000899061, ENST00000899062, ENST00000899063, ENST00000899064, ENST00000927927, ENST00000927928, ENST00000961878, ENST00000961879, ENST00000961880, ENST00000961881, ENST00000961882, ENST00000961883, ENST00000961884, ENST00000961885, ENST00000961886, ENST00000961887, ENST00000961888, ENST00000961889

RefSeq mRNA: 3 — MANE Select: NM_001136019 NM_001136019, NM_001411064, NM_004107

CCDS: CCDS12770, CCDS92663

Canonical transcript exons

ENST00000221466 — 7 exons

Exon	Start	End
ENSE00000954709	49525457	49525573
ENSE00001192687	49513387	49513473
ENSE00001509905	49512661	49512750
ENSE00003487124	49513882	49514133
ENSE00003572960	49514211	49514486
ENSE00003579012	49524507	49524776
ENSE00003888717	49526010	49526428

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 99.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.2115 / max 996.5980, expressed in 1634 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177010	16.4901	1571
177008	15.2158	1424
177012	4.2671	1236
177014	0.6170	209
177011	0.6011	202
177013	0.0188	6
177015	0.0017	1

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	99.23	gold quality
monocyte	CL:0000576	98.98	gold quality
endocervix	UBERON:0000458	98.97	gold quality
right lobe of liver	UBERON:0001114	98.93	gold quality
spleen	UBERON:0002106	98.92	gold quality
omental fat pad	UBERON:0010414	98.91	gold quality
right ovary	UBERON:0002118	98.87	gold quality
peritoneum	UBERON:0002358	98.86	gold quality
small intestine Peyer’s patch	UBERON:0003454	98.86	gold quality
transverse colon	UBERON:0001157	98.79	gold quality
left uterine tube	UBERON:0001303	98.77	gold quality
right lung	UBERON:0002167	98.75	gold quality
left ovary	UBERON:0002119	98.74	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.71	gold quality
granulocyte	CL:0000094	98.70	gold quality
leukocyte	CL:0000738	98.67	gold quality
mononuclear cell	CL:0000842	98.65	gold quality
mucosa of stomach	UBERON:0001199	98.56	gold quality
small intestine	UBERON:0002108	98.55	gold quality
gall bladder	UBERON:0002110	98.52	gold quality
stromal cell of endometrium	CL:0002255	98.49	gold quality
body of uterus	UBERON:0009853	98.48	gold quality
upper lobe of left lung	UBERON:0008952	98.46	gold quality
right coronary artery	UBERON:0001625	98.45	gold quality
nerve	UBERON:0001021	98.39	gold quality
tibial nerve	UBERON:0001323	98.39	gold quality
rectum	UBERON:0001052	98.33	gold quality
upper lobe of lung	UBERON:0008948	98.23	gold quality
colonic epithelium	UBERON:0000397	98.19	gold quality
duodenum	UBERON:0002114	97.93	gold quality

Single-cell (SCXA)

Detected in 28 experiment(s), a significant marker in 26.

Experiment	Marker?	Max mean expression
E-MTAB-7407	yes	3356.29
E-MTAB-9906	yes	2541.15
E-MTAB-6678	yes	1909.96
E-MTAB-8495	yes	1680.78
E-MTAB-8530	yes	974.32
E-CURD-112	yes	850.34
E-MTAB-10042	yes	649.84
E-MTAB-8205	yes	442.91
E-HCAD-1	yes	95.27
E-MTAB-6701	yes	90.74
E-HCAD-4	yes	76.42
E-CURD-122	yes	66.57
E-HCAD-10	yes	64.01
E-MTAB-10553	yes	57.61
E-MTAB-8410	yes	48.34

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ELF1, GATA1, GLI2, HMGA1, NFKB1, NFKB, NFKBIA, PAX3, RELA, SPI1, STAT1, STAT4, USF1, USF2

miRNA regulators (miRDB)

10 targeting FCGRT, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-374B-3P	98.63	68.24	1360
HSA-MIR-4266	98.53	67.29	1035
HSA-MIR-2467-5P	97.36	67.71	991
HSA-MIR-4790-5P	96.67	67.45	167
HSA-MIR-4636	91.87	64.93	40

Literature-anchored findings (GeneRIF, showing 40)

• Human FcRn binds selectively to human, rabbit and guinea pig IgG but not significantly to rat, bovine, sheep or mouse IgG (except for weak binding to mouse IgG2b). (PMID:11717196)
• Assembly of the FcRn alpha-chain with beta(2)microglobulin is important for both transport of FcRn from the ER to the cell surface and efficient pH-dependent IgG binding. (PMID:12006623)
• Functional reconstitution in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin (PMID:12023961)
• although a secreted soluble form of human FcRn does not dimerize, the membrane-anchored receptor can form both non-covalent and covalent dimers; dimerization of human FcRn occurs in the absence of its ligand, IgG (PMID:12144784)
• Expression of FcRn is demonstrated along the human fetal intestine and in a human nonmalignant fetal intestinal epithelial cell line (H4), which by location indicates that FcRn could play a role in the uptake and transport of IgG in the human fetus. (PMID:12538789)
• data show that it is possible to confer binding of mouse immunoglobulin G on human FcRn by mutagenesis of selected residues; observations are of direct relevance to understanding the molecular nature of the human FcRn-IgG interaction (PMID:12972260)
• Analysis of the dynamics and properties of trafficking of FcRn in live microvascular endothelial cells shows that the primary site at which FcRn sorts IgGs for either salvage or lysosomal degradation is the sorting endosome. (PMID:14764666)
• strong cell surface polarity displayed by hFcRn results from dominant basolateral sorting by motifs in the cytoplasmic tail that nonetheless allows for a cycle of bidirectional transcytosis (PMID:14767057)
• FCRN is involved in IgG exocytosis. (PMID:15258288)
• residues encompassing and extending away from the interaction site on the alpha2 helix of FcRn play a significant and most likely indirect role in FcRn-IgG interactions (PMID:15644205)
• expression of a functional FcRn in normal human epidermal keratinocytes. (PMID:15654966)
• FcRn leaves sorting endosomes in Rab4(+)Rab11(+) or Rab11(+) compartments (PMID:15689494)
• These transport and localization data are in accordance with efficient hFcRn-mediated apical IgG recycling and basolateral directed IgG transcytosis in placental trophoblasts. (PMID:16229888)
• FcRn binds IgG and albumin, salvages both from a degradative fate, and maintains their physiologic concentrations (PMID:16549777)
• a variable number of tandem repeats promoter polymorphism influences the expression of the FcRn receptor, leading to different IgG-binding capacities (PMID:16805790)
• FcRn fulfills a major role in IgG-mediated phagocytosis (PMID:16849638)
• FcRn-mediated recycling is a major contributor to the high endogenous concentrations of IgG and serum albumin, two important plasma proteins. (PMID:17046328)
• Our results show clear evidence that the conserved H166 is a key player in the FcRn-albumin interaction. (PMID:17048273)
• Elucidation of intracellular recycling pathways leading to exocytosis of FCRN was facilitated by using multifocal plane micoscopy. (PMID:17384151)
• Neonatal Fc receptor (FcRn) was expressed in various cells of the human skin (including keratinocytes, melanocytes, and histiocytes). (PMID:17674040)
• This review summarizes FcRn biology. (PMID:17703228)
• These data provide the first evidence that NF-kappaB signaling via intronic sequences regulates FcRn expression and function. (PMID:17709515)
• These results suggest a novel mechanism for regulation of IgG transport by calmodulin-dependent sorting of FcRn and its cargo away from a degradative pathway and into a bidirectional transcytotic route. (PMID:18003977)
• JAK/STAT-1 signaling pathway was necessary and sufficient to mediate the down-regulation of FcRn gene expression by IFN-gamma (PMID:18566411)
• A previously undescribed role for FcRn in mediating the presentation of antigens by dendritic cells when antigens are present as a complex with antibody, is shown. (PMID:18599440)
• The impact of two free cysteine residues (C48 and C251) of the FcRn heavy chain on the overall structure and function of soluble human FcRn is explored. (PMID:18637944)
• Intracellular trafficking of FcRn is regulated by its intrinsic sorting information and/or an interaction with major histocompatibility (MHC) class II invariant chain (Ii). (PMID:18684948)
• Results indicate that FcRn-dependent internalization of IgG may be important not only in cells taking up IgG from an extracellular acidic space, but also in endothelial cells participating in homeostatic regulation of circulating IgG levels. (PMID:18843053)
• N-glycans in FcRn contribute significantly to the steady-state membrane distribution and direction of IgG transport in polarized epithelia. (PMID:19164298)
• The role of hFcRn in IgG transport and trafficking in syncytiotrophoblasts cultures in vitro. (PMID:19362735)
• a single structurally and functionally heterogeneous recycling endosome compartment that traffics FcRn to both cell surfaces while discriminating between recycling and transcytosis pathways polarized in their direction of transport (PMID:19451275)
• It plays a role in intracellular IGG transfer and immune surveillance. (review) (PMID:19462839)
• VNTR polymorphisms within the FCGRT promoter are not associated with LN in the Chinese population. (PMID:19772792)
• A recombinant truncated HSA variant, HSA(Bartin), does not interact with FcRn, which gives a molecular explanation for the low serum levels. (PMID:20006594)
• No binding of albumin was observed at physiological pH to neonatal Fc receptor. At acidic pH, a 100-fold difference in binding affinity was observed. (PMID:20018855)
• Affinities to FcRn of clinically used therapeutic proteins are closely correlated with the serum half-lives reported from clinical studies, and suggest an important role of FcRn in regulating the serum half-lives of the therapeutic proteins. (PMID:20083659)
• promoter polymorphism is not associted with the rate of maternal-fetal IgG transfer (PMID:20452034)
• the x-ray crystal structure of a representative monomeric peptide in complex with human FcRn (PMID:20592032)
• influence of FcRn expression on disease phenotype and the catabolism of therapeutically administered intravenous immunoglobulins in 28 patients with common variable immunodeficiency (PMID:20627700)
• Thirty-three genetic variations of FCGRT, including 17 novel ones, were found. (PMID:20930418)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	mhc1uma	ENSDARG00000039164
danio_rerio		ENSDARG00000059039
danio_rerio	mhc1uba	ENSDARG00000075963
danio_rerio	mhc1uka	ENSDARG00000092731
mus_musculus	Fcgrt	ENSMUSG00000003420
rattus_norvegicus	Fcgrt	ENSRNOG00000020583

Paralogs (22): HFE (ENSG00000010704), ULBP1 (ENSG00000111981), ULBP2 (ENSG00000131015), ULBP3 (ENSG00000131019), MR1 (ENSG00000153029), RAET1L (ENSG00000155918), CD1D (ENSG00000158473), CD1A (ENSG00000158477), CD1C (ENSG00000158481), CD1B (ENSG00000158485), CD1E (ENSG00000158488), AZGP1 (ENSG00000160862), RAET1E (ENSG00000164520), RAET1G (ENSG00000203722), MICB (ENSG00000204516), MICA (ENSG00000204520), HLA-C (ENSG00000204525), HLA-E (ENSG00000204592), HLA-G (ENSG00000204632), HLA-F (ENSG00000204642), HLA-A (ENSG00000206503), HLA-B (ENSG00000234745)

Protein

Protein identifiers

IgG receptor FcRn large subunit p51 — P55899 (reviewed: P55899)

Alternative names: IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor

All UniProt accessions (14): P55899, A0A024QZI2, A0AB39TY97, A0AB39TYH5, A0AB39TZ17, M0QYM4, M0QYN1, M0QYN9, M0R0A9, M0R0H0, M0R0K7, M0R220, M0R266, M0R2T3

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation. In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB. (Microbial infection) Acts as an uncoating receptor for a panel of echoviruses including Echovirus 5, 6, 7, 9, 11, 13, 25 and 29.

Subunit / interactions. FcRn complex consists of two subunits: p51, and p14 which is equivalent to beta-2-microglobulin. It forms an MHC class I-like heterodimer. Interacts with albumin/ALB; this interaction regulates ALB homeostasis. (Microbial infection) Interacts with Echovirus 6, Echovirus 11 and Echovirus 30 capsid protein VP1.

Subcellular location. Cell membrane. Endosome membrane.

Tissue specificity. Expressed in full-term placenta, heart, lung, liver, muscle, kidney, pancreas, and both fetal and adult small intestine.

Similarity. Belongs to the immunoglobulin superfamily.

RefSeq proteins (3): NP_001129491, NP_001397993, NP_004098 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003006	Ig/MHC_CS	Conserved_site
IPR003597	Ig_C1-set	Domain
IPR007110	Ig-like_dom	Domain
IPR011161	MHC_I-like_Ag-recog	Domain
IPR011162	MHC_I/II-like_Ag-recog	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR037055	MHC_I-like_Ag-recog_sf	Homologous_superfamily
IPR050208	MHC_class-I_related	Family

Pfam: PF00129, PF07654

UniProt features (49 total): strand 21, helix 8, turn 4, region of interest 4, disulfide bond 2, sequence conflict 2, topological domain 2, signal peptide 1, chain 1, modified residue 1, glycosylation site 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

31 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
6C98	X-RAY DIFFRACTION	1.85
6QIO	X-RAY DIFFRACTION	1.95
6C97	X-RAY DIFFRACTION	2
6C99	X-RAY DIFFRACTION	2
6NHA	X-RAY DIFFRACTION	2.38
6LA6	ELECTRON MICROSCOPY	2.39
4K71	X-RAY DIFFRACTION	2.4
6WNA	X-RAY DIFFRACTION	2.4
9MI6	X-RAY DIFFRACTION	2.41
6QIP	X-RAY DIFFRACTION	2.45
6WOL	X-RAY DIFFRACTION	2.49
5WHK	X-RAY DIFFRACTION	2.5
3M17	X-RAY DIFFRACTION	2.6
9WYD	X-RAY DIFFRACTION	2.65
1EXU	X-RAY DIFFRACTION	2.7
6LA7	ELECTRON MICROSCOPY	2.82
5BXF	X-RAY DIFFRACTION	2.85
6FGB	X-RAY DIFFRACTION	2.9
7B5F	ELECTRON MICROSCOPY	2.9
9OC6	X-RAY DIFFRACTION	2.97
4N0F	X-RAY DIFFRACTION	3.02
9OC7	X-RAY DIFFRACTION	3.07
7XXA	ELECTRON MICROSCOPY	3.09
3M1B	X-RAY DIFFRACTION	3.1
5BJT	X-RAY DIFFRACTION	3.2
7C9V	ELECTRON MICROSCOPY	3.3
7Q15	X-RAY DIFFRACTION	3.3
6ILM	ELECTRON MICROSCOPY	3.4
9DBT	X-RAY DIFFRACTION	3.4
4N0U	X-RAY DIFFRACTION	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P55899-F1	85.73	0.74

Antibody-complex structures (SAbDab): 4 — 5WHK, 6FGB, 6NHA, 9MI6

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 334

Disulfide bonds (2): 119–182, 221–275

Glycosylation sites (1): 125

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 292 (showing top): MODULE_52, JI_RESPONSE_TO_FSH_UP, GOLDRATH_IMMUNE_MEMORY, MODULE_45, MODULE_64, GOCC_CELL_SURFACE, MODULE_478, HSIAO_HOUSEKEEPING_GENES, GOBP_VESICLE_MEDIATED_TRANSPORT, MODULE_308, MODULE_75, WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP, CASORELLI_APL_SECONDARY_VS_DE_NOVO_UP, ZHAN_V1_LATE_DIFFERENTIATION_GENES_UP, MODULE_88

GO Biological Process (2): IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor (GO:0002416), immune response (GO:0006955)

GO Molecular Function (3): IgG binding (GO:0019864), beta-2-microglobulin binding (GO:0030881), protein binding (GO:0005515)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), external side of plasma membrane (GO:0009897), endosome membrane (GO:0010008), endosome (GO:0005768), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immunoglobulin transcytosis in epithelial cells	1
immune system process	1
response to stimulus	1
immunoglobulin binding	1
protein binding	1
binding	1
plasma membrane	1
cell surface	1
side of membrane	1
endosome	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
endomembrane system	1
cytoplasmic vesicle	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1640 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FCGRT	ALB	P02768	997
FCGRT	B2M	P01884	972
FCGRT	FCGR1A	P12314	883
FCGRT	FCGR2A	P12318	857
FCGRT	FCGR2B	P31994	855
FCGRT	FCGR3A	P08637	837
FCGRT	FCGR3B	O75015	738
FCGRT	SUCO	Q9UBS9	735
FCGRT	FCAR	P24071	733
FCGRT	TRIM21	P19474	680
FCGRT	PIGR	P01833	679
FCGRT	FCER1G	P30273	659
FCGRT	ERBB2	P04626	655
FCGRT	TNFRSF8	P28908	652
FCGRT	TNF	P01375	647

IntAct

47 interactions, top by confidence:

A	B	Type	Score
FCGRT	B2M	psi-mi:“MI:0407”(direct interaction)	0.690
FCGRT	CLDN19	psi-mi:“MI:0915”(physical association)	0.560
FCGRT	NINJ2	psi-mi:“MI:0915”(physical association)	0.560
FCGRT	FAM3C	psi-mi:“MI:0915”(physical association)	0.560
UPK2	FCGRT	psi-mi:“MI:0915”(physical association)	0.560
FCGRT	PMP22	psi-mi:“MI:0915”(physical association)	0.560
SCGB1D1	FAM234B	psi-mi:“MI:0914”(association)	0.530
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
B2M	KPNA3	psi-mi:“MI:0914”(association)	0.530
CD1B	TOR1B	psi-mi:“MI:0914”(association)	0.530
CD1E	SUSD5	psi-mi:“MI:0914”(association)	0.530
FCGRT	ALB	psi-mi:“MI:0407”(direct interaction)	0.440
FCGRT	LILRB2	psi-mi:“MI:0915”(physical association)	0.400
LILRA2	FCGRT	psi-mi:“MI:0915”(physical association)	0.400
HLA-E	RTL8C	psi-mi:“MI:0914”(association)	0.350
ATP1B4	RTN2	psi-mi:“MI:0914”(association)	0.350
KLRC1	METTL15	psi-mi:“MI:0914”(association)	0.350
CD1E	ADAM10	psi-mi:“MI:0914”(association)	0.350
CITED1	RAD21	psi-mi:“MI:0914”(association)	0.350
HES4	CTSV	psi-mi:“MI:0914”(association)	0.350
GFRA3	B3GAT3	psi-mi:“MI:0914”(association)	0.350
ELP4	HSPA8	psi-mi:“MI:0914”(association)	0.350
STK36	ARAF	psi-mi:“MI:0914”(association)	0.350
FRAT2	GSK3A	psi-mi:“MI:0914”(association)	0.350
KLF5	GSK3A	psi-mi:“MI:0914”(association)	0.350

BioGRID (170): FCGRT (Affinity Capture-MS), FCGRT (Affinity Capture-MS), FCGRT (Affinity Capture-MS), FCGRT (Affinity Capture-MS), FCGRT (Affinity Capture-MS), FCGRT (Affinity Capture-MS), THBS1 (Affinity Capture-MS), DUSP9 (Affinity Capture-MS), PRTG (Affinity Capture-MS), FCGRT (Affinity Capture-MS), SGCE (Affinity Capture-MS), FGFR4 (Affinity Capture-MS), HGFAC (Affinity Capture-MS), PCDHGA11 (Affinity Capture-MS), FCGRT (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2K7V7, C1ITJ8, O08602, O08603, O08604, O19477, O35799, P01901, P01902, P06339, P13599, P14427, P14432, P16391, P25311, P26151, P30383, P55899, P60018, P70387, Q01965, Q29980, Q29983, Q2KN22, Q30201, Q3B8P2, Q5RD09, Q60I18, Q61559, Q63678, Q64726, Q6H3X3, Q8HWB0, Q8HWE5, Q8HWE7, Q8SPV9, Q8VD31, Q920A9, Q95460, Q9BCU3

Diamond homologs: O00241, O46631, P55899, P78324, P97710, P97797, Q29980, Q5JXA9, Q5TFQ8, Q9H106, Q9P1W8, Q9PWR4, C1ITJ8, O19477, O35799, O73895, P01870, P01889, P01893, P01894, P01895, P01896, P01897, P01898, P01899, P01900, P01901, P01902, P01909, P03991, P04223, P04439, P06140, P06339, P10321, P11609, P13747, P13748, P13749, P13750

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 44 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	6	18.0×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
adaptive immune response	5	11.7×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	1
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1443 predictions. Top by Δscore:

Variant	Effect	Δscore
19:49514485:GG:G	donor_gain	1.0000
19:49514486:GG:G	donor_gain	1.0000
19:49524708:GCGA:G	donor_gain	1.0000
19:49525554:GA:G	donor_gain	1.0000
19:49526008:A:AG	acceptor_gain	1.0000
19:49526009:G:GA	acceptor_gain	1.0000
19:49526009:GCCCC:G	acceptor_gain	1.0000
19:49514106:G:GT	donor_gain	0.9900
19:49514486:GGT:G	donor_loss	0.9900
19:49514488:T:TC	donor_loss	0.9900
19:49524591:C:CA	acceptor_gain	0.9900
19:49524699:TCAA:T	donor_gain	0.9900
19:49524711:A:G	donor_gain	0.9900
19:49525532:G:GT	donor_gain	0.9900
19:49525555:A:G	donor_gain	0.9900
19:49526007:CAGC:C	acceptor_loss	0.9900
19:49526008:A:C	acceptor_loss	0.9900
19:49526009:GC:G	acceptor_gain	0.9900
19:49526009:GCC:G	acceptor_gain	0.9900
19:49526009:GCCC:G	acceptor_gain	0.9900
19:49512391:G:T	donor_gain	0.9800
19:49512515:G:GG	donor_gain	0.9800
19:49512540:G:GT	donor_gain	0.9800
19:49512546:G:GT	donor_gain	0.9800
19:49512578:GC:G	donor_gain	0.9800
19:49514482:GAAGG:G	donor_gain	0.9800
19:49514489:G:GG	donor_loss	0.9800
19:49524505:A:AG	acceptor_gain	0.9800
19:49524506:G:GG	acceptor_gain	0.9800
19:49524669:G:GT	donor_gain	0.9800

AlphaMissense

2336 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:49514030:G:C	W74C	0.997
19:49514030:G:T	W74C	0.997
19:49514240:T:A	C119S	0.997
19:49514241:G:C	C119S	0.997
19:49514335:G:C	W150C	0.997
19:49514335:G:T	W150C	0.997
19:49524581:T:C	F226L	0.997
19:49524583:C:A	F226L	0.997
19:49524583:C:G	F226L	0.997
19:49524674:T:C	F257L	0.997
19:49524676:C:A	F257L	0.997
19:49524676:C:G	F257L	0.997
19:49514060:G:C	W84C	0.996
19:49514060:G:T	W84C	0.996
19:49514377:G:C	W164C	0.995
19:49514377:G:T	W164C	0.995
19:49514429:T:A	C182S	0.995
19:49514430:G:C	C182S	0.995
19:49524609:T:C	F235S	0.995
19:49514240:T:C	C119R	0.994
19:49514429:T:C	C182R	0.994
19:49514431:C:G	C182W	0.994
19:49524568:C:G	C221W	0.994
19:49514028:T:A	W74R	0.993
19:49514028:T:C	W74R	0.993
19:49514241:G:A	C119Y	0.993
19:49514333:T:A	W150R	0.993
19:49514333:T:C	W150R	0.993
19:49514430:G:A	C182Y	0.993
19:49514442:T:C	L186P	0.993

dbSNP variants (sampled 300 via entrez): RS1000021938 (19:49513479 G>A,C), RS1000499647 (19:49522207 G>A), RS1000512107 (19:49518578 G>C,T), RS1000910403 (19:49511136 A>C), RS1000946663 (19:49518197 C>T), RS1001031073 (19:49511776 G>A,C,T), RS1001179655 (19:49526866 C>T), RS1001239971 (19:49513220 A>C,G,T), RS1001441071 (19:49512596 G>A), RS1001796563 (19:49523734 C>T), RS1001829099 (19:49523508 C>T), RS1002018372 (19:49515307 G>A,T), RS1002229115 (19:49511457 C>T), RS1002509830 (19:49525254 G>A), RS1002625421 (19:49520033 A>G,T)

Disease associations

OMIM: gene MIM:601437 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST000583_10	Hematological and biochemical traits	3.000000e-08
GCST001698_11	Serum total protein levels	3.000000e-06
GCST001698_4	Serum total protein levels	7.000000e-08
GCST001699_1	Serum albumin levels	8.000000e-07
GCST001699_11	Serum albumin levels	6.000000e-09
GCST005988_17	Serum albumin levels	2.000000e-40
GCST005999_24	Aspartate aminotransferase levels	6.000000e-10
GCST006034_25	Total cholesterol levels	6.000000e-10
GCST010243_95	Apolipoprotein B levels	3.000000e-10
GCST010244_274	Triglyceride levels	3.000000e-16
GCST90002383_291	Hematocrit	1.000000e-15
GCST90002384_460	Hemoglobin	5.000000e-14
GCST90002400_93	Plateletcrit	3.000000e-09
GCST90002403_307	Red blood cell count	6.000000e-13
GCST90002405_432	Reticulocyte count	4.000000e-10

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0004747	protein measurement
EFO:0004536	total blood protein measurement
EFO:0004736	aspartate aminotransferase measurement
EFO:0004574	total cholesterol measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004530	triglyceride measurement
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0007985	platelet crit
EFO:0004305	erythrocyte count
EFO:0007986	reticulocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5966 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Immunoglobulin C1-set domain-containing proteins

Most potent curated ligand interactions (4 total), top 4:

Ligand	Action	Affinity	Parameter
nipocalimab	Binding	10.36	pKd
DX-2507	Binding	8.74	pKd
rozanolixizumab	Binding	8.7	pKd
ziltivekimab	Binding	6.65	pKd

ChEMBL bioactivities

218 potent at pChembl≥5 of 331 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.80	IC50	1.6	nM	CHEMBL1090633
8.62	IC50	2.4	nM	CHEMBL1090632
8.62	IC50	2.4	nM	CHEMBL1090970
8.59	IC50	2.6	nM	CHEMBL2304309
8.41	IC50	3.9	nM	CHEMBL1090278
8.41	IC50	3.9	nM	CHEMBL1090640
8.38	IC50	4.2	nM	CHEMBL1090968
8.34	IC50	4.6	nM	CHEMBL1090638
8.33	IC50	4.7	nM	CHEMBL1090636
8.32	IC50	4.8	nM	CHEMBL2304310
8.30	IC50	5	nM	CHEMBL1090637
8.28	IC50	5.2	nM	CHEMBL1090635
8.25	IC50	5.6	nM	CHEMBL1090639
7.75	IC50	18	nM	CHEMBL1090279
7.70	IC50	20	nM	CHEMBL1090969
7.51	Kd	31	nM	CHEMBL443697
7.51	Kd	31	nM	CHEMBL1089948
7.37	Kd	43	nM	CHEMBL500475
7.37	Kd	43	nM	CHEMBL1089946
7.36	Kd	44	nM	CHEMBL526174
7.34	Kd	46	nM	CHEMBL525265
7.30	IC50	50	nM	CHEMBL1090280
7.24	Kd	58	nM	CHEMBL503983
7.23	Kd	59	nM	CHEMBL504423
7.21	Kd	62	nM	CHEMBL1089949
7.17	Kd	67	nM	CHEMBL503673
7.14	Kd	73	nM	CHEMBL504003
7.13	Kd	74	nM	CHEMBL504003
7.13	Kd	74	nM	CHEMBL1089949
7.07	Kd	86	nM	CHEMBL525614
6.99	Kd	103	nM	CHEMBL486090
6.96	Kd	110	nM	CHEMBL505899
6.96	Kd	110	nM	CHEMBL506195
6.85	Kd	140	nM	CHEMBL2304308
6.82	Kd	150	nM	CHEMBL1089947
6.80	Kd	160	nM	CHEMBL524887
6.77	Kd	170	nM	CHEMBL446284
6.77	Kd	170	nM	CHEMBL443697
6.77	Kd	170	nM	CHEMBL1089948
6.72	Kd	190	nM	CHEMBL525636
6.70	Kd	200	nM	CHEMBL504855
6.70	Kd	200	nM	CHEMBL509409
6.66	Kd	220	nM	CHEMBL504837
6.64	Kd	230	nM	CHEMBL508564
6.64	Kd	230	nM	CHEMBL503489
6.62	Kd	240	nM	CHEMBL506623
6.60	Kd	250	nM	CHEMBL506647
6.58	Kd	260	nM	CHEMBL501395
6.58	Kd	260	nM	CHEMBL1089946
6.55	Kd	280	nM	CHEMBL501541

PubChem BioAssay actives

218 with measured affinity, of 445 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N’-[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N-[2-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]ethyl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0016	uM
N’-[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N-[2-[[2-[[3-[[3-[[3-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-oxopropyl]amino]-3-oxopropyl]amino]-3-oxopropyl]amino]-2-oxoethyl]-methylamino]ethyl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0024	uM
N,N’-bis[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0024	uM
N’-[(2S)-1-[[(2S)-1-[[(4R,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N-[2-[[2-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]ethyl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0026	uM
N’-[(2S)-1-[[(2S)-1-[[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-26-[(1R)-1-hydroxyethyl]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22-trimethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decazatricyclo[36.3.1.011,15]dotetracontan-23-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N-[2-[[2-[[(2S)-1-[[(2S)-1-[[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-26-[(1R)-1-hydroxyethyl]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22-trimethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decazatricyclo[36.3.1.011,15]dotetracontan-23-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]ethyl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0039	uM
(4S,7S,16S,19S,25S,28R,33R,36S)-28-[[(2S)-2-[[(2S)-2-[[2-[2-[[2-[[(4S,7S,16S,19S,25S,28R,33R,36S)-28-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-16-benzyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carbonyl]amino]acetyl]amino]ethyl-methylamino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-16-benzyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carboxamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0039	uM
(4S,7S,16S,19S,25S,28R,33R,36S)-28-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-N-[2-[2-[2-[[2-[[(4S,7S,16S,19S,25S,28R,33R,36S)-28-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-16-benzyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carbonyl]amino]acetyl]amino]ethylamino]ethylamino]-2-oxoethyl]-16-benzyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carboxamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0042	uM
(2S)-N,N’-bis[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-methylbutanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0046	uM
(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-28-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carboxamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0047	uM
(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-28-[[(2S)-2-[[(2S)-2-[3-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carboxamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0048	uM
N,N’-bis[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-3,3-dimethylpentanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0050	uM
N-[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N’-[2-[[4-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-oxobutanoyl]-methylamino]ethyl]-N’-methylbutanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0052	uM
(2S)-N,N’-bis[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28R,33R,36S)-16-benzyl-33-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-methylpentanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0056	uM
N’-[(2S)-1-[[(2S)-1-[[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decazatricyclo[36.3.1.011,15]dotetracontan-23-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N-[2-[[2-[[(2S)-1-[[(2S)-1-[[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decazatricyclo[36.3.1.011,15]dotetracontan-23-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]ethyl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0180	uM
N,N’-bis[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(4S,7S,16S,22S,25R,30R,33S)-16-[(4-carbamimidamidophenyl)methyl]-30-carbamoyl-22-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-8,11,26,26-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,32-decaoxo-27,28-dithia-1,5,8,11,14,17,20,23,31-nonazabicyclo[31.3.0]hexatriacontan-25-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0200	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0310	uM
(4S,7S,16S,19S,25S,28R,33R,36S)-28-[[(2S)-2-[[(2S)-2-acetamido-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-16-benzyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11,29,29-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,35-undecaoxo-30,31-dithia-1,5,8,11,14,17,20,23,26,34-decazabicyclo[34.3.0]nonatriacontane-33-carboxamide	476767: Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0310	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[(3R)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-2-oxopiperidin-1-yl]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0430	uM
(5S,8S,15S,18R,23R,26S,32S,35S,38S)-23-[[(2S)-2-[[(2S)-2-acetamido-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-35-benzyl-26-[(1R)-1-hydroxyethyl]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22-trimethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decazatricyclo[36.3.1.011,15]dotetracontane-18-carboxamide	476767: Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0430	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[(3R)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-2-oxoazepan-1-yl]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0440	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0460	uM
N’-[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28S,36S,39S)-16-benzyl-36-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11-dimethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,30,38-dodecaoxo-1,5,8,11,14,17,20,23,26,31,37-undecazabicyclo[37.3.0]dotetracontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-N-[2-[[2-[[(2S)-1-[[(2S)-1-[[(4S,7S,16S,19S,25S,28S,36S,39S)-16-benzyl-36-carbamoyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11-dimethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,30,38-dodecaoxo-1,5,8,11,14,17,20,23,26,31,37-undecazabicyclo[37.3.0]dotetracontan-28-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]ethyl]butanediamide	476766: Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	ic50	0.0500	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0580	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0590	uM
(4S,7S,16S,22S,25R,30R,33S)-25-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-16-[[4-(diaminomethylideneamino)phenyl]methyl]-22-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-8,11,26,26-tetramethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,32-decaoxo-27,28-dithia-1,5,8,11,14,17,20,23,31-nonazabicyclo[31.3.0]hexatriacontane-30-carboxamide	476767: Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0620	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-pyridin-4-ylpropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0670	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(4-carbamimidamidophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404557: Binding affinity to human FcRn at pH 7.4 by surface plasmon resonance assay	kd	0.0730	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.0860	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[(3R)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-2-oxoazepan-1-yl]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1030	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1100	uM
(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(3-methyl-1,3-thiazol-3-ium-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]-N-[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]pyrrolidine-2-carboxamide	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1100	uM
(4S,7S,16R,19S,25S,28S,36S,39S)-28-[[(2S)-2-[[(2S)-2-acetamido-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-16-benzyl-25-[(1R)-1-hydroxyethyl]-4-[(4-hydroxyphenyl)methyl]-19-(1H-imidazol-4-ylmethyl)-8,11-dimethyl-7-(2-methylpropyl)-2,3,6,9,12,15,18,21,24,27,30,38-dodecaoxo-1,5,8,11,14,17,20,23,26,31,37-undecazabicyclo[37.3.0]dotetracontane-36-carboxamide	476767: Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1400	uM
(5S,8S,15S,18R,23R,26S,32S,35S,38S)-23-[[(2S)-2-[[(2S)-2-acetamido-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-35-benzyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decazatricyclo[36.3.1.011,15]dotetracontane-18-carboxamide	476767: Binding affinity to soluble human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1500	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[(3R)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-2-oxopiperidin-1-yl]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1600	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1700	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]-methylamino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.1900	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2000	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-methylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2000	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(4-aminophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2200	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-1-[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2300	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2300	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2400	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2500	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404557: Binding affinity to human FcRn at pH 7.4 by surface plasmon resonance assay	kd	0.2600	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2800	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[(3R)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-2-oxopyrrolidin-1-yl]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.2800	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-sulfanylbutanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.3100	uM
(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.3100	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2R)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.3100	uM
(2S)-1-[2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid	404556: Binding affinity to human FcRn at pH 6 by surface plasmon resonance assay	kd	0.3200	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, affects cotreatment, increases expression, affects expression	3
Benzo(a)pyrene	affects methylation, decreases expression	3
Cyclosporine	decreases expression	3
Aflatoxin B1	affects expression, affects methylation, decreases expression, increases methylation	3
bisphenol S	decreases expression, decreases methylation	2
Diethylhexyl Phthalate	decreases expression, increases abundance, increases methylation	2
Tretinoin	increases expression	2
Valproic Acid	affects expression, increases methylation	2
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	decreases expression	1
beta-lapachone	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases methylation, increases abundance	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
sulindac sulfide	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
nivalenol	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
K 7174	decreases expression	1
oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine	affects expression, increases reaction	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Zoledronic Acid	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Vehicle Emissions	affects expression, increases reaction	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1114459	Binding	Inhibition of IgG binding to soluble human FcRn after 5 hrs by competition ELISA	Synthesis and structure-activity relationships of dimeric peptide antagonists of the human immunoglobulin G-human neonatal Fc receptor (IgG-FcRn) interaction. — J Med Chem

Cellosaurus cell lines

3 cell lines: 2 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2X0	Abcam HEK293T FCGRT KO	Transformed cell line	Female
CVCL_E5I8	CHO-K1/FcRn	Spontaneously immortalized cell line	Female
CVCL_E6QF	Genomeditech CHO-K1 H_FCGRT(FcRn)+B2M	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.